Development of techniques for the early detection of cancer by blood test

Toru Mochizuki, Deputy Director and Director of Medical Genetics Shizuoka Cancer Center Research Institute
(FY2010-2012)

Aims and Expected Results of Research

Based on results from a previous urban area study identifying a protein called Proneurotensin (ProNT) that secretes the small cell lung cancer cell line SBC3, we are aiming to commercialize a highly efficient small cell lung cancer diagnosis kit that utilizes a blood test using ProNT as a tumor marker. Furthermore, the establishment of ProNT as the next-generation ProGRP marker is expected to contribute to the early diagnosis and treatment of small cell lung cancer.

FY2011 results

1. We conducted research utilizing clinical samples of prototype ProNT measurement kits. Our results confirmed we had fully met the requirements in regards to sensitivity and specificity to begin steps for the review and productization of said kits.
2. We defined the areas to be investigated in the next clinical trials for the kits' commercialization.
3. We are also moving forward with clinical research preparations in association with businesses interested in our product.